Delcath Systems (NASDAQ:DCTH) Stock Rating Upgraded by StockNews.com

Delcath Systems (NASDAQ:DCTH) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Friday.

Several other research firms have also recently commented on DCTH. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price on shares of Delcath Systems in a research report on Friday, October 18th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $21.00 target price on shares of Delcath Systems in a research report on Friday, October 18th. Stephens reaffirmed a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. Finally, Craig Hallum initiated coverage on shares of Delcath Systems in a research report on Friday, June 28th. They issued a “buy” rating and a $18.00 target price for the company. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $21.50.

Delcath Systems Stock Up 0.3 %

Shares of DCTH opened at $10.68 on Friday. The stock has a market capitalization of $296.75 million, a P/E ratio of -4.03 and a beta of 0.78. The firm has a fifty day simple moving average of $9.47 and a two-hundred day simple moving average of $7.94. Delcath Systems has a twelve month low of $2.25 and a twelve month high of $11.74.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.12). The firm had revenue of $7.77 million for the quarter, compared to analysts’ expectations of $5.00 million. Delcath Systems had a negative net margin of 474.22% and a negative return on equity of 312.48%. During the same period in the previous year, the company earned ($0.58) EPS. Sell-side analysts expect that Delcath Systems will post -1.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Delcath Systems

Hedge funds have recently bought and sold shares of the business. Riverwater Partners LLC bought a new stake in Delcath Systems during the third quarter worth about $161,000. Levin Capital Strategies L.P. boosted its stake in Delcath Systems by 12.2% during the first quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock worth $262,000 after acquiring an additional 5,969 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Delcath Systems during the second quarter worth about $370,000. Renaissance Technologies LLC bought a new stake in Delcath Systems during the second quarter worth about $694,000. Finally, Marshall Wace LLP boosted its stake in Delcath Systems by 7.0% during the second quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock worth $776,000 after acquiring an additional 6,066 shares in the last quarter. Institutional investors own 61.12% of the company’s stock.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.